Close Menu

NEW YORK (GenomeWeb News) – DxS today said that it has entered into a partnership with AstraZeneca to potentially market a companion diagnostic for the drug firm's gefitinib (Iressa) treatment for non small cell lung cancer.

DxS said that its TheraScreen EGFR29 Mutation Kit will be used to test the mutation status of patients' EGFR oncogene to identify their eligibility for treatment with Iressa. Manchester, UK-based DxS has already CE-marked the TheraScreen EGFR29 Mutation Kit.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.

A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.

Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.

In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.